Brian Lee, MD, is a hepatologist and liver transplant specialist with Keck School of Medicine of USC.

Alcohol use among US adults declined between 2022 and 2024, marking the first confirmed reduction since the onset of the COVID-19 pandemic, according to a national cross-sectional study published in Annals of Internal Medicine.¹˒² Any alcohol use fell by nearly 2%, and heavy drinking fell by more than 8%, though both remain above 2018 levels.¹˒²

"It's encouraging to see alcohol use decline for the first time since the start of the pandemic," said Brian P. Lee, MD, MAS, 

 and liver transplant specialist with Keck Medicine of USC and principal investigator of the study in a statement. "However, use remains above pre-pandemic levels and certain groups continue to have concerning trends."²

Lee and colleagues analyzed National Health Interview Survey data from 114,352 US adults between 2018 and 2024, classifying heavy drinking by National Institute on Alcohol Abuse and Alcoholism criteria.² These criteria define heavy drinking as ≥5 drinks per day or ≥15 drinks per week for men and ≥4 drinks per day or ≥8 drinks per week for women.²

The declines were uneven across age groups. Gen Z adults showed the largest drop in any alcohol use, at more than 5%, while heavy drinking among millennials fell by 17% between 2022 and 2024.² Among adults aged 50 to 64, any alcohol use rose by nearly 4% and heavy drinking rose by more than 36% from 2018 to 2024.²

Men saw a larger decline in any alcohol use than women (2.4% vs 1.1%), while women saw a larger decline in heavy drinking (9% vs 7.7%).²

In the following interview, Lee discusses what clinicians can do to sustain the decline, why adults aged 50 to 64 remain a concern, and how much pandemic-era drinking explains the rise in alcohol-associated liver disease.

Q&A: Declining Alcohol Use and Heavy Drinking in Adults 50 to 64

: What can clinicians and patients do to help the recent decline in alcohol use continue?

Brian P. Lee, MD, MAS: The decline occurred largely independent of clear clinical intervention as far as we know. What clinicians can do is to stop relying on patients to bring alcohol use up in conversation. Alcohol use should be asked about at every visit, like smoking, with a validated screen like the AUDIT-C, and for patients where the history is uncertain there's now a biomarker, phosphatidylethanol, that gives an objective measure of intake over the prior 4 weeks. 

The thresholds for heavy drinking are lower than most patients and a fair number of physicians assume, so being knowledgeable about those thresholds (≥15 drinks per week or ≥5 drinks on any given day for men and ≥8 drinks per week or ≥4 drinks on any given day for women) is important. Physician messaging is part of this too. Many patients, and some physicians, still believe a glass of wine a day is good for the heart. That idea came from observational studies that compared drinkers with abstainers who had often quit because they were already sick, and when that bias is accounted for, the protective effect largely disappears. 

The current evidence is that cancer and liver risk can begin even at low alcohol levels and rise with dose, and the message coming from physicians should reflect that. A patient who hears "moderate drinking is fine" from their doctor has no reason to cut back. And when a patient does meet criteria for alcohol use disorder, we have effective medications that are prescribed far less often than they should be.

HCPLive: Heavy drinking among adults 50 to 64 rose by more than a third since 2018. What are the implications for liver disease in this group?

Brian P. Lee, MD, MAS: This is the group in which the combination of exposure and timing is most concerning. Fibrosis accumulates over decades, so a 55-year-old who increased their drinking in 2020 is often adding to damage that's already there rather than starting from a healthy liver. 

This is also the decade when cirrhosis and hepatocellular carcinoma most often declare themselves, and there's less physiologic reserve to absorb an insult. In practical terms, patients with heavy drinking, particularly those above the age of 50, should be considered for liver fibrosis screening.

HCPLive: Women reduced heavy drinking more than men, yet their alcohol-associated liver disease has been rising faster. What might explain that discrepancy?

Brian P. Lee, MD, MAS: The reduction from 2022 to 2024 is real, but it's a recent step down from a large step up. Heavy drinking among women is still about 13% above 2018, and I should mention that in this survey the prevalence of heavy drinking among women is now slightly higher than among men, because the thresholds are sex-specific and women's drinking has been converging with men's for years. 

Women develop fibrosis at lower cumulative exposure, they progress faster once it's established, and the increase in women's drinking predated the pandemic by at least a decade. So the liver disease we're seeing in women now reflects 15 or 20 years of rising intake. Two years of modest decline won't change that trajectory quickly.

We've also published on co-factors for the rise in alcohol-associated liver disease; if a co-factor rises in prevalence, alcohol-associated liver disease can increase even if alcohol consumption is stable. In a separate study that we published in Annals of Internal Medicine a couple years ago, we showed that the rise of metabolic syndrome among women may be contributing to the rise in alcohol-associated liver disease, independent of changes in alcohol consumption.

HCPLive: With drinking now falling, to what extent do you attribute the rise in alcohol-associated liver disease among young adults to pandemic-era drinking?

Brian P. Lee, MD, MAS: Only partly. Alcohol-associated hepatitis in young adults was rising well before 2020, and the pandemic accelerated a trend rather than creating one. If younger adults' drinking stays below 2018 levels, I'd expect those acute presentations to ease sooner than the cirrhosis burden in older patients. 

That's a hypothesis rather than something this study can show, and it doesn't account for co-factors of alcohol-associated liver disease that are changing in prevalence independent of alcohol consumption.

Editor's Note: This transcript has been edited for grammar and clarity using artificial intelligence tools. Lee reports consulting for Gilead Sciences, Novo Nordisk, GlaxoSmithKline, Altimmune, Bausch Health, and others.

Ayyala-Somayajula D, Dodge JL, Lee BP. Alcohol use between 2018 and 2024: a national cross-sectional study. 

. Published online September 22, 2026. doi:10.7326/ANNALS-26-01824

Keck Medicine of USC. U.S. alcohol use falls for first time since the COVID-19 pandemic, but remains above pre-pandemic levels. Published September 21, 2026. Accessed September 30, 2026. 

https://news.keckmedicine.org/us-alcohol-use-falls-for-first-time-since-the-covid-19-pandemic-but-remains-above-pre-pandemic-levels/

Articles

Alcohol use among US adults declined from 2022 to 2024, with any drinking dropping nearly 2% and heavy drinking falling more than 8%, although both remain above 2018 baselines. Trends diverged by cohort: Gen Z had the largest reduction in any use, while adults aged 50–64 increased both any use and heavy drinking substantially since 2018. Sustaining declines requires routine screening (eg, AUDIT-C), objective testing when history is unclear (phosphatidylethanol), and updated counseling on cancer/liver risk even at low intake.

Heavy drinking rose >36% since 2018 among middle-aged adults. A hepatologist on screening, sex-specific thresholds, and pandemic effects.

Addiction

Addiction medicine condition center page, resources on the topics of medical news and expert insight into clinical addiction can be found. Content includes articles, interviews, videos, podcasts, and breaking news on addiction therapy research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

US Alcohol Use Falls, but Not for Adults Aged 50 to 64, With Brian Lee, MD

Gerald Appel, MD, is a professor of clinical medicine, director of clinical nephrology, and director of the Glomerular Disease Center at Columbia University.

Andrew Bomback, MD, MPH, is an assistant professor of medicine at Columbia University Medical Center.

Proteinuria Response in Fibrillary GN: What Defines a Non-Responder

Andrew Bomback, MD, MPH, opens the segment by asking Gerald Appel, MD, how he defines a non-responder in fibrillary glomerulonephritis (FGN) in practice, how long patients should remain on therapy, and what numbers signal that treatment is not working.

Appel separates the question into two parts. Early response is measured by a reduction in proteinuria, which correlates with better outcomes across many glomerular diseases and appears to do so in FGN as well, with lower baseline proteinuria also associated with better outcomes. The ultimate endpoint, he explains, is the glomerular filtration rate and serum creatinine. With any new therapy, Appel expects to need 6 months to a year to see an initial signal and to gather data suggesting a patient is doing well long term without significant adverse effects.

The discussion shifts to where the FACT trial of ACTH with or without tacrolimus fits over longer follow-up. Bomback highlights a stark divergence between responders and non-responders over the 2 years patients were studied. At 24 months, none of the complete responders had reached end-stage kidney disease, suggesting that marked proteinuria reduction offered apparent protection against progression. In contrast, none of the non-responders showed a stable GFR, with 45% experiencing significant GFR decline and 55% progressing to end-stage kidney disease.

Bomback cautions that proteinuria is unlikely ever to be accepted as a formal surrogate endpoint in FGN. Unlike IgA nephropathy, where large natural history datasets allowed validation of proteinuria as a surrogate marker, the disease is simply too rare. Still, he emphasizes that there is a clear signal that early and significant proteinuria reduction offers the best chance of a good long-term kidney outcome, consistent with what clinicians see across many glomerular diseases.

The segment concludes with Bomback identifying the key open question in FGN management: which drug or combination of drugs can reliably achieve that early, significant drop in proteinuria.

Videos

Video Series

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

 and significant reductions in ischemic heart disease mortality, other subtypes are still holding the top spot in US causes of mortality.

Heart disease has been the foremost cause of death in the United States for over a century. In the 1970s, heart disease accounted for >700,000 of roughly 2.3 million deaths across all ages and both sexes, with the next most common, malignant neoplasms, coming in at just under 550,000. However, in recent years, substantial improvements in medical technology, specifically targeted interventions for 

, and other major risk factors, and advancements in the management and prevention of acute myocardial infarction (AMI) have led to a significant decline in ischemic heart disease mortality.

Despite these substantial strides, recent research has suggested that decreases in ischemic heart disease mortality are actively counterbalanced by increases in mortality from other cardiovascular conditions, including hypertensive heart disease, 

. Clinicians have attributed these rising mortality rates to a variety of factors, including an aging population with longer life expectancies, increased survivability of first cardiovascular events, and dramatically rising prevalence of major risk factors such as obesity, physical inactivity, diabetes, and hypertension.

To address this discrepancy and evaluate the trajectory of cardiovascular care moving forward, the 

 editorial team sat down with Jesus Almendral, MD, director of the cardiology fellowship program and medical director of the Advanced Heart Failure and LVAD Program at Hackensack Meridian Jersey Shore University Medical Center, and Kanika Mody, MD, medical director of the Surgical Ventricular Assist Device (VAD) Program at Hackensack Meridian Hackensack University Medical Center.

“I think that we’re catching patients earlier with a cardiovascular or ischemic disease – we’ve done a relatively decent job with promoting proper screening of ischemic cardiomyopathy, ischemic disease, and these patients are actually living longer and are now starting to have other issues develop,” Mody told 

. “A lot of other disease processes are also living longer, so now we’re getting a combination of inflammatory processes, like diabetes and hypertension, that are really dominating the landscape of our cardiac patients.”

A recent study from the American Heart Association, published in 2025, more specifically examined these shifting mortality trends. Accessing mortality data for US adults ≥25 years from 1970 to 2022, investigators utilized International Classification of Disease (ICD) codes to determine the underlying cause of death related to heart disease. During the study, deaths were reported as absolute number and age-adjusted rates, with annual age-adjusted mortality rates utilizing the 2000 census as the standard population.

Between 1970 and 2022, the US population of adults ≥25 years rose from 108.9 million to 229 million, while life expectancy lengthened from 70.9 years to 77.5. The National Vital Statistics System recorded 119,152,492 deaths in total, of which 37,276,835 (31%) were attributable to heart disease. 1970 saw 733,273 heart disease deaths, of which 666,257 were ischemic and 67,016 were attributed to other heart diseases. However, in 2022, investigators found 701,443 heart disease deaths, of which 371,360 were ischemic and 330,083 were from other heart disease.

Age-adjusted mortality for AMI decreased by 89% over this period, from 354 per 100,000 in 1970 to 40 per 100,000 in 2022. Age-adjusted mortality for chronic ischemic heart disease also fell by 71%, from 343 per 100,000 in 1970 to 98 per 100,000 in 2022. Additionally, the age-adjusted mortality for all heart disease, ischemic and otherwise, decreased by 66%, from 761 per 100,000 in 1970 to 258 per 100,000 in 2022.

However, age-adjusted mortality for other heart disease subtypes increased by 81%, from 68 per 100,000 to 123 per 100,000, in the same time period. Heart failure, hypertensive heart disease, and arrhythmia saw the most substantial growth in mortality, rising from 13 to 32 per 100,000, 16 to 33 per 100,000, and 2 to 11 per 100,000, respectively. Pulmonary heart disease, nonrheumatic valvular disease, and cardiac arrest also saw substantial increases from 1970 to 2022.

Ultimately, investigators attributed a significant proportion of these increases to multiple underlying factors. Among these was growth in several heart disease risk factors, including obesity, diabetes, and hypertension. From 1970 to 2022, obesity prevalence rose from 15% to 40%, while diabetes affected roughly half of US adults in 2020. Additionally, hypertension has seen a monumental and continuous surge since the beginning of the 21st century.

Ultimately, the investigators concluded that, while great progress has been made in curbing ischemic heart disease mortality, further effort is necessary to balance out the increase in other cardiovascular deaths. The growing challenge of these heart conditions is somewhat mitigated by their preventability. To this end, Almendral suggests that clinicians focus on modifiable risk factors, such as obesity and physical activity, to manage the ongoing challenge.

“The estimated length of survival has increased from 70 years to about 77 years, and because of that, people are living longer and are surviving more often with heart disease, with hypertension, diabetes, hyperlipidemia, and so on,” Almendral said. “Trying to control diabetes, trying to control hypertension, asking people to be more active, and making sure that their lipid panels are under control; those are the things that I think will prevent further heart failure down the road, further hypertensive heart disease, and further arrhythmias.”

Editors’ Note: Almendral reports minor honoraria from Abbott and Boston Scientific. Mody reports no relevant disclosures.

King SJ, Wangdak Yuthok TY, Bacong AM, et al. Heart disease mortality in the United States, 1970 to 2022. Journal of the American Heart Association. 2025;14(13). 

The Center for Disease Control: National Center for Health Statistics, National Vital Statistics System. Leading causes of death, 1990–1998. Accessed September 30, 2026. 

https://www.cdc.gov/nchs/data/dvs/lead1900_98.pdf

US heart disease mortality has fallen markedly since 1970, driven by steep declines in acute myocardial infarction and chronic ischemic heart disease deaths amid better prevention and treatment of major risk factors. However, these gains are increasingly offset by rising mortality from nonischemic cardiovascular conditions, particularly heart failure, hypertensive heart disease, and arrhythmias, in the context of population aging and higher survival after initial events. Parallel increases in obesity, diabetes, and hypertension appear to be key contributors, reinforcing the importance of aggressive risk-factor modification.

Jesus Almendral, MD, and Kanika Mody, MD, join the HCPLive team to discuss increases in hypertensive heart disease, heart failure, and other conditions.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Features

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Arrhythmia

Dyslipidemia

Cardiovascular Disease Still Top Cause of US Mortality Despite Recent Advancements

Fibrillary Glomerulonephritis in 2026: Why Treatment Remains a Challenge

Fibrillary glomerulonephritis (FGN) remains one of the least-studied glomerular diseases in nephrology, accounting for less than 1% of kidney biopsies and offering clinicians few evidence-based treatment options.

With DNAJB9 staining now able to separate FGN from look-alike entities and data available from the multicenter FACT trial, clinicians have a clearer, if still incomplete, framework for management.

In this 8-part HCPLive special report, "Management of Fibrillary Glomerulonephritis in 2026," Gerald Appel, MD, co-director of the Glomerular Kidney Center at Columbia University Irving Medical Center, is joined by fellow co-director Andrew Bomback, MD, MPH, to discuss how they approach diagnosis, treatment, and non-response in this ultra-rare disease.

The segment opens with Bomback asking what makes FGN so difficult to treat compared with other glomerular diseases. Appel points to rarity as the core obstacle. Because diagnosis depends entirely on kidney biopsy, he explains, enrolling enough patients to study the disease, or even to follow its natural history, has been hard. He adds that FGN was historically confused with immunotactoid glomerulonephritis, an entirely different disease, and that better markers should support more studies and collaboration going forward.

The conversation then turns to the FACT trial, a multicenter study conducted at glomerular centers across the United States in patients with DNAJB9-positive FGN. Bomback describes a design that randomized patients to ACTH alone or ACTH plus tacrolimus. He emphasizes that the trial's success begins with its completion, which demonstrated that patients with FGN can be enrolled in randomized studies that generate robust data.

Bomback notes that about 56% of patients across both arms achieved a complete or partial proteinuria remission by 12 months, establishing ACTH, alone or with tacrolimus, as an antiproteinuric option for some patients. He cautions, however, that nearly half of patients did not respond and that durability remains unknown, particularly whether proteinuria rebounds once therapy stops.

Appel closes the segment by noting that both he and Bomback co-authored the study. He acknowledges its limitations, including the lack of a placebo control, limited follow-up, and small numbers, while observing that it is the evidence clinicians currently have.

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

European Academy of Dermatology and Venereology (EADV) Congress 2026

 in Vienna, Austria, brought a broad mix of dermatology news spanning acne, hidradenitis suppurativa, atopic dermatitis, chronic spontaneous urticaria, basal cell carcinoma, and a cross-specialty environmental health analysis.

Highlights included 52-week durability data for an oral FASN inhibitor in acne, a phase 2b primary endpoint hit in HS, positive phase 2 findings for a long-acting anti-IL-13 antibody in atopic dermatitis, and new pooled quality-of-life data for dupilumab in omalizumab-naive CSU. An early-phase oncology readout and a large international registry study linking climate change to skin disease worsening rounded out the day.

Check out our rundown of the top 5 headlines from day 1.

Denifanstat Sustains Acne Control Through 52 Weeks, With Neal Bhatia, MD

Full 52-week results from a phase 3 open-label extension trial showed denifanstat, an oral fatty acid synthase (FASN) inhibitor, maintained acne control in patients with moderate to severe acne vulgaris with a favorable long-term safety profile. Treatment success was achieved by 57.8% of patients on continuous denifanstat and 55.6% of those who switched from placebo, with no discontinuations due to adverse events reported across the extension period.

Tulisokibart Shows Phase 2b Efficacy in Moderate to Severe HS

Tulisokibart met its HiSCR50 primary endpoint at 16 weeks in the phase 2b MK-7240-012 trial in patients with moderate to severe hidradenitis suppurativa. The results add to a growing body of evidence for TL1A-targeted therapy across inflammatory skin and gastrointestinal diseases.

APEX Part B: Zumilokibart Achieves Primary Endpoint in Atopic Dermatitis

All 3 doses of zumilokibart met the EASI-75 primary endpoint versus placebo at week 16 in AbbVie's phase 2 APEX Part B trial in atopic dermatitis. The findings mark a positive early readout for the long-acting anti-IL-13 antibody, which is also being evaluated across asthma and COPD.

Climate Change Tied to Skin Disease Worsening in 42% of Countries

The international SkinObservatory study found climate-related worsening of skin disease in 42% of countries surveyed, with the burden disproportionately concentrated in low-income nations. The findings, presented at EADV 2026, add large-scale epidemiological weight to growing concerns about environmental drivers of dermatologic disease.

CUPID A and C: Dupilumab Improves Quality of Life in Omalizumab-Naive CSU

A pooled analysis of the CUPID A and C trials found dupilumab improved overall Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) scores and 22 of 23 individual items versus placebo at 24 weeks in patients with omalizumab-naive chronic spontaneous urticaria. The data support dupilumab's patient-reported outcome benefit in a CSU population not previously treated with the current standard-of-care biologic.

Intralesional BO-112 Attains 61% Response in Basal Cell Carcinoma

Intralesional BO-112, a nanoplexed polyinosinic-polycytidylic acid (poly I:C) innate immune agonist, met its main endpoint in the phase 2b SPOTLIGHT-204 trial, with 61% of patients with resectable basal cell carcinoma achieving a response. The results position BO-112 as an early-stage candidate for neoadjuvant or localized immunotherapy approaches in BCC.

Day 1 EADV 2026 showcased late-stage dermatology readouts and broader environmental epidemiology. Denifanstat demonstrated 52-week durability in moderate-to-severe acne with sustained treatment success and no AE-driven discontinuations. In hidradenitis suppurativa, TL1A inhibition with tulisokibart achieved HiSCR50 at week 16. A long-acting anti–IL-13 antibody, zumilokibart, met EASI-75 across all doses at week 16 in atopic dermatitis. Dupilumab improved CU-Q2oL outcomes in omalizumab-naive CSU. Climate-linked disease worsening and intralesional BO-112 activity in resectable BCC rounded out highlights.

Check out highlights from news published on Day 1 of the EADV Congress 2026, spanning CSU, atopic dermatitis, HS, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

EADV Congress 2026: Day 1 Recap — 6 Headlines to Know

Bhatia discusses 52-week extension data showing denifanstat sustained acne control with a favorable long-term safety profile, presented at EADV 2026.

Acne

The HCPLive acne page is a resource for medical news and expert insights on dermatological disease. This page features expert-led coverage, articles, videos, and research on the therapies and development of treatments for chronic acne, and more.

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for 

. He is also the executive producer of two podcasts: 

. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Tulisokibart met its HiSCR50 primary endpoint at 16 weeks in the phase 2b MK-7240-012 trial assessing moderate to severe hidradenitis suppurativa.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Abigail Brooks is a strategic content lead overseeing 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Preview the biggest anticipated FDA decisions of Q4 2026, including bepirovirsen for CHB, obinutuzumab for pMN, bezuclastinib for systemic mastocytosis, and more.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Q4 2026 Preview: 7 FDA Decisions to Watch

Intralesional BO-112 met its main endpoint in the phase 2b SPOTLIGHT-204 trial, with 61% of patients with resectable basal cell carcinoma responding.

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

Zasocitinib achieved PASI 100 in 36.5% of patients vs 13.9% with deucravacitinib at week 16 in the phase 3 LATITUDE Atlas psoriasis trial.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

EADV 2026: Zasocitinib Tops Deucravacitinib for PASI 100 in Plaque Psoriasis

The international SkinObservatory study found climate-related skin disease disproportionately affecting low-income nations at EADV 2026.

All 3 zumilokibart doses met the EASI-75 primary end point vs placebo at Week 16 in AbbVie's phase 2 APEX Part B atopic dermatitis study.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dupilumab improved overall CU-Q2oL scores and 22 of 23 items vs placebo at 24 weeks in omalizumab-naive CSU, per a pooled CUPID A and C analysis.

Urticaria

The HCPLive urticaria page is a comprehensive resource for clinical news and insights on chronic idiopathic urticaria and chronic spontaneous urticaria. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for urticaria, and more.

Newly published results from the TRIUMPH-1 study have indicated the direct correlation between the triple agonist and several improvements to weight.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Retatrutide Improves Weight Loss, Knee Osteoarthritis Pain, Sleep Apnea Versus Placebo

Kristina Derrick, MD, is a dermatologist and clinical assistant professor at SUNY Downstate Health Sciences University.

Kristina Derrick, MD, explains how prior authorization and cost limit steroid-sparing care, and how dermatologists can document corticosteroid exposure. 

Latest News

US Alcohol Use Falls, but Not for Adults Aged 50 to 64, With Brian Lee, MD

Proteinuria Response in Fibrillary GN: What Defines a Non-Responder

Cardiovascular Disease Still Top Cause of US Mortality Despite Recent Advancements

Fibrillary Glomerulonephritis in 2026: Why Treatment Remains a Challenge

EADV Congress 2026: Day 1 Recap — 6 Headlines to Know